The Reality Check: Why ESG in Pharma Must Now Prove its Value

Let’s start with an uncomfortable question.

Is ESG reporting in the pharmaceutical industry still something you delegate, or has it become something you personally oversee?

Because the industry has crossed a quiet but decisive line, ESG is no longer a side document, a sustainability chapter at the back of an annual report, or a response to investor questionnaires. It is now shaping how regulators judge resilience, how investors assess risk, and how society measures trust.

And the signals are no longer subtle. 

• Europe’s CSRD.
• The SEC’s climate disclosures.
• Global pressure for transparency across value chains.

Together, they are asking pharma leaders one thing:

Do you understand your impact well enough to stand behind it publicly, consistently, and under audit?

From “Nice to Have” to “No Way Around It”

For years, ESG in the pharmaceutical industry has lived in a comfortable grey zone. Important, yes. Urgent, not always. Reports were published, commitments were made, and targets were announced.

But today, regulators are no longer interested in intent. They are interested in evidence. They want to see how climate risk flows into financial risk.

How supply chain decisions affect emissions and access. How governance structures actually function, not just how they are described.

This is the real shift leaders need to recognise:

ESG reporting is no longer about storytelling. It is about systems.

Regulatory Convergence: Coincidence or Course Correction?

Is it accidental that Europe, the U.S., and global standard setters are all moving in the same direction?

Unlikely.

The EU’s Corporate Sustainability Reporting Directive (CSRD) doesn’t just ask pharma companies to disclose more. It asks them to disclose in the same language, under assurance, across environmental, social, and governance dimensions.

Meanwhile, the SEC is framing climate risk as a financial materiality issue, not an ethical one. That distinction matters. It moves ESG out of CSR and squarely into boardrooms, audit committees, and investor calls.

When different regulators begin to ask similar questions, it’s usually a sign of something deeper: The market wants comparability. And leadership demands credibility.

Why Pharma Cannot Treat ESG Like Other Industries Do?

Let’s be honest. Pharma doesn’t get to play by generic rules.

Your products save lives. Your supply chains are global and fragile. Your manufacturing is energy-intensive and compliance-heavy.

Your reputation is built on trust.

So when stakeholders ask about emissions, water use, access to medicines, clinical trial diversity, or ethical governance, they’re not asking abstract questions. They’re asking whether the industry that protects health is also protecting the systems that sustain it.

That puts pharma leaders in a unique position. ESG here isn’t peripheral. It’s philosophical.

What Leading Companies Are Quietly Doing Differently?

The most prepared organisations aren’t scrambling to comply. They’re redesigning how information flows. Some of the strongest signals are coming not from press releases, but from how these companies operate internally.

Take Novartis, for example. Over the last few years, the company has invested heavily in mapping Scope 3 emissions across its supplier network, not as a one-time exercise, but as an ongoing data capability. Instead of relying solely on estimates, Novartis works directly with strategic suppliers to improve primary data quality, integrating sustainability metrics into procurement decisions. Scope 3 is treated as a business dependency, not a reporting footnote.

At Roche, ESG data is increasingly managed with the same discipline as financial data. Sustainability metrics are subject to internal controls, traceability, and third-party assurance, mirroring the standards of financial reporting. This allows leadership to answer a critical question regulators and investors are now asking: not just what you report, but how confident you are in the numbers.

AstraZeneca offers another instructive example. Climate and sustainability risks are embedded into enterprise risk management, discussed alongside supply continuity, regulatory exposure, and operational resilience. ESG is not parked with a sustainability function; it is elevated to board-level oversight, reinforcing the idea that environmental and social risks are also business risks.

Then there’s Sanofi, which has been explicit about strengthening board-level sustainability literacy. Rather than treating ESG as an awareness topic, Sanofi integrates sustainability expertise into its governance structures, ensuring that strategic decisions regarding manufacturing, partnerships, and innovation reflect long-term environmental and societal impacts. This is a subtle but powerful shift: sustainability is no longer interpreted through headlines, but through strategic consequence.

What unites these organisations is not a single framework or tool. It’s a shared mindset.

They are asking themselves 3 hard questions early:

• Do we truly understand where our Scope 3 emissions come from, or are we relying on assumptions?
• Could we defend our ESG data under regulatory scrutiny and independent assurance?
• Are sustainability risks reviewed with the same seriousness as financial and operational risks?

These companies recognize something others are still adjusting to: regulatory convergence is not a reporting challenge, but rather an operating model challenge. And those who redesign their systems now are buying themselves credibility, resilience, and strategic headroom for what comes next.

The Real Challenge Isn’t Reporting. It’s Integration.

Let’s call it what it is.

The hardest part of ESG reporting isn’t carbon accounting or social metrics. It’s alignment.

Alignment between:

• Sustainability teams and finance
• Operations and compliance
• Strategy and execution
• Leadership intent and organisational reality

And yes, that requires uncomfortable conversations. About suppliers. About legacy systems. About where the data is weak or inconsistent.

But here’s the counter-question leaders should be asking:

If we can manage clinical trials across continents, can we really say ESG integration is too complex?

Final Thoughts

ESG reporting is often framed as a burden. But history suggests something else.

Every major regulatory shift in the pharmaceutical industry, from GMP to pharmacovigilance and data integrity, has initially felt burdensome. Over time, it became a marker of excellence.

ESG is following the same path. The question is no longer whether pharma will align with converging ESG frameworks.

The question is who will lead that alignment — and who will be forced into it.

And that, ultimately, is a leadership decision.